Last Updated: November 16, 2026

Details for Patent: 10,077,271

« Back to Dashboard


Which drugs does patent 10,077,271 protect, and when does it expire?

Patent 10,077,271 protects KOMZIFTI and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 10,077,271
Title:Methods and compositions for inhibiting the interaction of menin with MLL proteins
Abstract:The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
Inventor(s):Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Szymon Klossowski
Assignee: Wellspring Biosciences LLC , University of Michigan System , Kura Oncology Inc
Application Number:US15/829,604
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,077,271

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kura KOMZIFTI ziftomenib CAPSULE;ORAL 220305-001 Nov 13, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,077,271

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 104020 ⤷  Start Trial
Australia 2016270002 ⤷  Start Trial
Brazil 112017026085 ⤷  Start Trial
Canada 2985053 ⤷  Start Trial
China 107922378 ⤷  Start Trial
China 116217581 ⤷  Start Trial
China 121800804 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.